Megan Brooks April 29, 2022 The US Food and Drug Administration (FDA) has approved mavacamten (Camzyos, Bristol Myers Squibb) to improve functional capacity and symptoms in adults with symptomatic New York Heart Association (NYHA) class II to III obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten is the first FDA-approved allosteric and reversible inhibitor selective for cardiac myosin...